Cytidine

Other Names

1-beta-Ribofuranosylcytosine1-β-D-Ribofuranosylcytosine1beta-2'-Ribofuranosylcytosine, d-1beta-D-Ribofuranosylcytosine1beta-Ribofuranosylcytosine2(1H)-Pyrimidinone, 4-amino-1-β-D-ribofuranosyl-4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one4-Amino-1-β-D-ribofuranosyl-2(1H)-pyrimidinone4-amino-1-β-D-ribofuranosylpyrimidin-2(1H)-one4-Amino-1beta-D-ribofuranosyl-2(1H)-pyrimidinonebeta-D-Ribofuranoside, cytosine-1CydCytidinCytosine ribosideCytosine β-D-ribosideCytosine, 1-β-D-ribofuranosyl-Cytosine-1-β-D-ribofuranosidecytosine-1beta-D-RibofuranosideNSC 20258Zytidinβ-D-Cytidine

Synopsis

Cytidine: A Comprehensive Reference

1. Identity, Chemical Description, and Common Preparations

Chemical Identity

Cytidine is defined as a nucleoside that consists of a pyrimidine base, specifically cytosine, linked to a ribose sugar. The first component is a nitrogen-containing base called cytosine, which belongs to a group of molecules known as pyrimidines; the second component is a five-carbon sugar molecule named ribose. These two parts are connected by a specific chemical link called a β-N1-glycosidic bond.

Cytidine has a chemical formula of C₉H₁₃N₃O₅ and a molecular weight of 243.22 g/mol. The melting point for cytidine is 230 °C. Cytidine is highly soluble in water, and it is a white, crystalline powder in appearance.

When a beta-N1-glycosidic bond between cytosine and a ribose ring occurs, cytidine is formed. Because it lacks a phosphate group, cytidine represents a nucleoside, rather than a nucleotide.

A closely related molecule is deoxycytidine, which is a building block for DNA. The primary difference is in the sugar component; deoxycytidine contains deoxyribose, which has one less hydroxyl (oxygen-hydrogen) group than the ribose found in cytidine.

Related Molecular Forms and Nomenclature

Cytidine exists in several phosphorylated forms of biological importance. Uridine–cytidine kinase can phosphorylate cytidine into cytidine monophosphate (CMP), and UMP/CMP kinase can phosphorylate CMP into cytidine diphosphate, which nucleoside diphosphate kinase can phosphorylate further into cytidine triphosphate (CTP).

Cytidine's most pharmacologically and commercially significant derivative is citicoline (also written CDP-choline). Citicoline is a naturally occurring chemical compound that supports brain function and health, also known as cytidine 5′-diphosphocholine or CDP-choline. When taken as a supplement, citicoline is hydrolyzed into choline and cytidine in the intestine. Once these cross the blood–brain barrier, they are reformed into citicoline by the rate-limiting enzyme in phosphatidylcholine synthesis, CTP-phosphocholine cytidylyltransferase.

Natural Sources

Dietary sources of cytidine include foods with high RNA (ribonucleic acid) content, such as organ meats, brewer's yeast, as well as pyrimidine-rich foods such as beer. During digestion, RNA-rich foods are broken down into ribosyl pyrimidines (cytidine and uridine), which are absorbed intact.

The circulating pyrimidines uridine and cytidine, besides being incorporated into nucleic acids, can serve as substrates for the salvage pathway of pyrimidine nucleotide synthesis; as precursors of the cytidine triphosphate (CTP) needed in the phosphatidylcholine (PC) and phosphatidylethanolamine (PE) biosynthetic pathway; and as precursors for the UDP (uridine diphosphate) and UTP (uridine triphosphate) that activate brain P2Y receptors and that promote brain glycogen synthesis via UDP-glucose.

In humans, the predominant circulating pyrimidine is uridine; in rats, it is cytidine. These variations probably reflect the species differences in cytidine deaminase, the enzyme that converts cytidine to uridine in the body.

Common Preparations and Forms

Pure cytidine is not a common dietary supplement; it is most often available as citicoline, also known as CDP-choline. Citicoline is available as a dietary supplement that is chemically identical to the naturally occurring compound. It belongs to a class of substances called nootropic agents, which are used to improve thinking ability and memory. The dietary supplement is available over the counter in the United States and as a prescription drug in Europe and Japan.

In a clinical setting, healthcare professionals may give citicoline therapy as a medication taken by mouth, as an injection into a muscle, or as an intravenous medication.

Nucleotides, the building blocks of RNA and DNA, play important roles in various biological processes, including gastrointestinal function, energy metabolism, and immune regulation. Nucleotides are widely present in food, and they are also used as additives for infant formulas due to the beneficial effects they provide to infants. The nucleotides added to infant formulas include cytidine-, disodium uridine-, adenosine-, disodium inosine-, and disodium guanosine- 5′-monophosphate.

2. Traditional and Historical Use

Cytidine as an isolated nucleoside does not have a distinct history of traditional use as such in any classical herbal or nutritional tradition. The compound was unknown as a discrete entity until the biochemical elucidation of nucleic acid structure in the twentieth century. Its use is therefore entirely modern and scientifically derived, grounded in an understanding of cellular biochemistry rather than empirical ethnobotanical practice.

Nonetheless, foods exceptionally rich in dietary nucleotides — including organ meats, brewer's yeast, and fermented beverages — have been consumed across cultures for millennia. Dietary sources of cytidine include foods with high RNA content, such as organ meats, brewer's yeast, as well as pyrimidine-rich foods such as beer. During digestion, RNA-rich foods are broken down into ribosyl pyrimidines (cytidine and uridine), which are absorbed intact. The deliberate consumption of organ meats across diverse cultures from ancient Egypt, Rome, and throughout East Asia would have provided substantial nucleoside intake, though without knowledge of its biochemical significance.

The first formal recognition of dietary nucleotides as potentially essential nutrients arrived with investigation of infant nutrition. The biologically relevant concentrations of Total Potentially Available Nucleosides (TPAN) in human milk were found to be higher than previously thought, at levels of 72 ± 24 mg/L. Recognition of nucleoside content in human breast milk as a potential explanatory factor in health differences between breastfed and formula-fed infants drove research interest from the 1980s onward. The Food Chemicals Codex in 2010 submitted to the FDA monographs on the individual nucleotides prepared by enzymatic hydrolysis of yeast RNA, for use in infant formula.

The Kennedy pathway — the primary biochemical route for phosphatidylcholine synthesis — is named after Eugene Kennedy, who elucidated it over 50 years ago. The discovery of cytidine coenzymes' function in phospholipid biosynthesis by Kennedy and Weiss in 1956 established the modern scientific rationale for cytidine as a supplemental nutrient and laid the conceptual groundwork for subsequent pharmaceutical investigation of citicoline.

3. Key Constituents and Mechanisms of Action

Structural Role in RNA

Cytidine is a component of RNA, contributing to the structure and function of nucleotides in nucleic acid sequences. As one of the four ribonucleosides of RNA, cytidine is present in every RNA molecule produced by living cells, making it foundational to gene expression, protein synthesis, and cellular regulation.

The Pyrimidine Salvage Pathway

In mammals, pyrimidine can be produced through a de novo synthesis pathway taking amino acids as substrates or a salvage pathway by uptake of the circulating pyrimidines in the bloodstream. Generally, the salvage pathway is the main pyrimidine source for resting or fully differentiated cells, while the de novo pathway is necessary for high-proliferating cells to meet the boosted requirement of pyrimidines.

Cytidine can either be converted to CMP by uridine kinase or deaminated by cytidine deaminase (CDD) to uridine and further processed to UMP. Cytidine can only be converted into uridine by cytidine deaminase (CDA). This interconversion between cytidine and uridine is central to cytidine's physiological fate following oral ingestion or endogenous production.

Cells obtain extracellular uridine and cytidine mainly through two nucleoside transporter families, SLC28A as well as SLC29A. Subsequently, uridine and cytidine are converted to UMP and CTP, respectively.

The Kennedy Pathway and Phospholipid Synthesis

The glycerophospholipids phosphatidylcholine (PC) and phosphatidylethanolamine (PE) account for greater than 50% of the total phospholipid species in eukaryotic membranes and thus play major roles in the structure and function of those membranes. In most eukaryotic cells, PC and PE are synthesized by an aminoalcoholphosphotransferase reaction, which uses sn-1,2-diradylglycerol and either CDP-choline or CDP-ethanolamine, respectively. This is the last step in a biosynthetic pathway known as the Kennedy pathway.

The two branches of the Kennedy pathways (CDP-choline and CDP-ethanolamine) are the predominant pathways responsible for the synthesis of the most abundant phospholipids, phosphatidylcholine and phosphatidylethanolamine, respectively, in mammalian membranes.

Phosphatidylcholine synthesis requires phosphocholine and cytidine triphosphate (CTP), a cytidine nucleotide, which is involved in the rate-limiting step. Because high-energy molecules cytidine diphosphocholine (CDP-choline) and cytidine diphosphoethanolamine (CDP-ethanolamine) are formed as precursors for the synthesis of PC and PE, respectively, the two branches of the Kennedy pathways are often referred to as the CDP-choline and CDP-ethanolamine pathways.

Blood–Brain Barrier Transport and Brain Metabolism

Only small amounts of circulating cytidine are converted to brain CTP, since the blood–brain barrier (BBB) high-affinity transporter for pyrimidines (CNT2) has a very low affinity for cytidine; uridine, in contrast, readily enters the brain via CNT2, yielding UTP which can then be converted to CTP by CTP synthase. CTP then reacts with phosphocholine to form endogenous CDP-choline, which combines with diacylglycerol (DAG), preferentially species containing PUFAs like DHA, EPA, or AA, to form PC.

Within the brain, cytidine has a close relationship with another nucleoside, uridine. The body can convert cytidine into uridine, and this is important for the brain because circulating uridine readily crosses the blood–brain barrier. This interconversion creates a flexible pool of pyrimidine nucleosides for the brain's specialized needs.

Exogenously administered CDP-choline is metabolized to cytidine and choline in rats, while it is metabolized to uridine and choline in humans. This species difference is pharmacologically important when interpreting animal studies involving cytidine supplementation.

Neuronal–Glial Glutamate Cycling

In addition to its role as a pyrimidine component of RNA, cytidine has been found to control neuronal-glial glutamate cycling, with supplementation decreasing midfrontal/cerebral glutamate/glutamine levels. As such, cytidine has generated interest as a potential glutamatergic antidepressant drug.

Cytidine Triphosphate as an Energy Carrier

The molecule's triphosphate form, CTP, participates in cellular metabolism. While not as universally used for energy transfer as adenosine triphosphate (ATP), CTP provides energy for specific biochemical reactions. Its role is particularly noted in the synthesis of glycerophospholipids.

4. Scientific Evidence by Area of Use

4.1 Neuropsychiatric Disorders: Bipolar Depression

Evidence level: Preliminary; one small double-blind RCT in humans.

Cytidine, a pyrimidine component of RNA that regulates dysfunctional neuronal-glial glutamate cycling, has been clinically evaluated in bipolar depression.

Thirty-five patients with bipolar depression were randomly assigned to receive the mood-stabilizing drug valproate plus either cytidine or placebo for 12 weeks. Midfrontal cerebral glutamate/glutamine levels were measured using proton magnetic resonance spectroscopy before and after 2, 4, and 12 weeks of oral cytidine administration.

Cytidine plus valproate improved depressive symptoms earlier than valproate plus placebo; the antidepressant effects observed in the cytidine group were positively associated with lower midfrontal glutamate/glutamine levels, suggesting that the therapeutic effects of cytidine supplementation in bipolar depression occur by lowering brain glutamate/glutamine levels.

This single trial formed the basis for cytidine's inclusion in a Cochrane-registered review of glutamate receptor modulators for bipolar disorder. Five studies (329 participants) were included in that review. All included studies were placebo-controlled and two-armed, and the glutamate receptor modulators — ketamine (two trials), memantine (two trials), and cytidine (one trial) — were used as add-on drugs to mood stabilisers. The treatment period for cytidine was 12 weeks of repeated administration.

One class of molecules with the potential to impact both energy metabolism and excitatory glutamatergic transmission in the brain is the pyrimidine nucleosides. These include uridine, triacetyluridine (a uridine prodrug), and cytidine. Pyrimidines have beneficial effects on cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function — each of which has been linked to the pathophysiology of bipolar disorder.

The available clinical evidence base for cytidine in bipolar depression is limited to a single small RCT (n=35). Independent replication in larger trials is lacking, and no definitive clinical recommendations can be drawn from current evidence.

4.2 Cognitive Function and Neuroprotection (via Citicoline)

Evidence level: Moderate for memory in older adults; mixed for stroke.

Because citicoline is hydrolyzed in the gut to yield cytidine and choline, research into citicoline's cognitive effects is directly relevant to understanding cytidine's biological activity in humans.

The EFSA Panel on Nutrition, Novel Foods and Food Allergens considered the food, citicoline (cytidine 5‐diphosphocholine, CDP-Choline) inner salt, sufficiently characterised. Improvement, maintenance or reduced loss of memory is a beneficial physiological effect for middle-aged or elderly adults encountering age-associated subjective memory impairment. The applicant identified three pertinent human intervention studies in healthy individuals that investigated the effect of citicoline on memory.

Cognitive enhancements attributed to citicoline have been most prominent among individuals with vascular cognitive impairment and Alzheimer's disease. Evidence from various studies shows citicoline may stabilize cognitive function, indicated by maintaining Mini-Mental State Examination (MMSE) scores over a 9-12 month period, particularly in those with mild vascular cognitive impairment.

For ischemic stroke, early evidence was hopeful but did not survive large-scale trial scrutiny. Some preliminary research suggested that citicoline may reduce the rates of death and disability following an ischemic stroke. However, the largest citicoline clinical trial to date — a randomised, placebo-controlled, sequential trial of 2,298 patients with moderate-to-severe acute ischaemic stroke in Europe — found no benefit of administering citicoline on survival or recovery from stroke.

4.3 Phospholipid Synthesis and Membrane Integrity

Evidence level: Well-established mechanistically; animal and in vitro evidence predominant.

Beyond its involvement in RNA, cytidine is a participant in the creation of phospholipids. These are fat molecules that form the primary structure of all cell membranes. Cytidine, in its activated form as cytidine triphosphate (CTP), facilitates the production of key phospholipids like phosphatidylcholine. This process, sometimes called the Kennedy pathway, is foundational for maintaining the integrity and fluidity of membranes.

Hereditary diseases associated with single gene mutations in the Kennedy pathways have been identified. Genetic diseases within the same pathway vary greatly, ranging from muscular dystrophy to spastic paraplegia to a childhood blinding disorder to bone deformations. These inherited disorders, while not treated with cytidine supplementation per se, demonstrate the fundamental importance of cytidine-mediated phospholipid synthesis to tissue health across multiple organ systems.

4.4 Lipid Metabolism and Gut Microbiota

Evidence level: Preclinical (animal) only. No human clinical data available.

Cytidine and uridine are endogenous metabolites in the pyrimidine metabolism pathway, and cytidine is a substrate that can be metabolized into uridine via cytidine deaminase. Uridine has been widely reported to be effective in regulating lipid metabolism. However, whether cytidine could ameliorate lipid metabolism disorder had not previously been investigated. In one animal study, ob/ob mice were used, and the effect of cytidine (0.4 mg/mL in drinking water for five weeks) on lipid metabolism disorder was evaluated in terms of an oral glucose tolerance test, serum lipid levels, liver histopathological analysis, and gut microbiome analysis.

The findings revealed that cytidine could alleviate certain aspects of dyslipidemia and improve hepatic steatosis via modulating the gut microbiota composition in ob/ob mice, especially increasing the abundance of short-chain fatty acids-producing microbiota. These results suggest that cytidine supplementation could be a potential therapeutic approach for dyslipidemia.

Important limitations of this study were acknowledged by the authors: first, the concentrations of short-chain fatty acids were not determined, and the lipid profiles in liver tissue were not fully investigated; second, only one dose of treatment was evaluated; third, OTUs were used in 16S rRNA amplicon data analysis instead of the more modern method of ASVs. No human clinical evidence exists for cytidine's effects on dyslipidemia.

4.5 Infant Nutrition and Immune Development

Evidence level: Moderate for nucleotide-supplemented formula broadly; cytidine-specific data limited.

Infants fed milk formula fortified with nucleotides had better responses to immunization as evidenced by an increase in humoral antibody response and increased cytokine production. Cytidine (as cytidine 5′-monophosphate, CMP) is one of several nucleotides added to infant formulas alongside UMP, AMP, GMP, and IMP to more closely approximate the nucleoside and nucleotide content of human breast milk.

Various forms of ribonucleic acid found in cells and biological fluids are required intermediaries in energy metabolism, glycoconjugate synthesis, and signal transduction. Nucleotides have been identified as conditionally essential nutrients, since their de novo presence in rapidly growing tissues is both a functional and structural requirement for proper cell function.

Studies conducted with formulae supplemented at these levels showed statistically significant effects on weight gain, decrease in the risk of diarrhoea, and improvement in certain immunological parameters.

4.6 Cancer Biology (Cytidine Analog Research)

Evidence level: Established for cytidine analogs as chemotherapy; not directly applicable to supplemental cytidine.

Cytidine analogs modified in position 5 of the pyrimidine ring, such as azacitidine, are potent inhibitors of DNA methylation. The hypomethylating effect of cytidine analogs appears to depend upon an altered chemical group at the 5 position of cytidine. Cytosine arabinoside and gemcitabine do not possess these differences. In vitro models with both azacitidine and its analog, decitabine, showed antitumor effects at high concentrations, while inducing differentiation at lower concentrations of primary leukemic blasts.

It is critical to note that these chemotherapeutic applications pertain to synthetic analogs of cytidine, not to unmodified cytidine itself. The pharmacological activity of azacitidine (5-azacytidine), gemcitabine, and cytarabine does not translate to equivalent activities of supplemental cytidine at nutritional doses.

Regarding physiological cytidine in the cancer context, research has explored the interplay between cytidine supplementation and enzyme expression in tumor cells. The expression of cytidine deaminase (CDA), which converts cytidine into uridine, is low in an important proportion of cancer cell lines and consistently low in neuroblastoma samples and in cell lines from neuroblastoma and small cell lung carcinoma. This suggested that in the presence of a DHODH inhibitor, an excess of cytidine would be deleterious for low-CDA-expressing cancer cell lines. This represents early-stage mechanistic research, not a clinical treatment strategy.

5. Body Systems and Health Areas of Association

Central Nervous System: Cytidine is a precursor to CTP, which drives phosphatidylcholine synthesis in neuronal membranes via the Kennedy pathway. It is also involved in glutamate–glutamine cycling between neurons and astroglia. Cytidine has been found to control neuronal-glial glutamate cycling, with supplementation decreasing midfrontal/cerebral glutamate/glutamine levels.
Cell Membranes: Phosphatidylcholine and phosphatidylethanolamine, whose synthesis depends on cytidine-derived intermediates, account for greater than 50% of the total phospholipid species in eukaryotic membranes.
Hepatic and Lipid Metabolism: Preclinical evidence indicates a potential role in lipid regulation via gut microbiota modulation. Cytidine could alleviate certain aspects of dyslipidemia and improve hepatic steatosis via modulating the gut microbiota composition in ob/ob mice, especially increasing the abundance of short-chain fatty acids-producing microbiota. Human evidence is absent.
Immune System: Cytidine supplementation can protect T cells from DHODH blockage, indicating a role in supporting immune cell survival under metabolic stress. In infant nutrition, nucleotide supplementation including CMP has been associated with enhanced immunological parameters.
Gastrointestinal System: Nucleotides play important roles in gastrointestinal function, energy metabolism, and immune regulation. In rapidly proliferating intestinal mucosal cells, the demand for nucleotides may exceed de novo synthesis capacity, making salvage-pathway sources important.
Mood and Psychiatric Function: Via its effects on glutamate neurotransmission, cytidine has been investigated in bipolar depression as an adjunct to mood stabilizers.

6. Dosage Forms and Dosages Reported in Studies

Cytidine as a standalone supplement is not widely standardized, and dedicated pharmacokinetic studies establishing optimal human dosages are scarce. The following represents dosage information specifically reported in identified studies:

Bipolar depression clinical trial (Yoon et al., 2009): Thirty-five patients with bipolar depression received valproate plus cytidine or placebo for 12 weeks, with midfrontal cerebral glutamate/glutamine levels measured at 2, 4, and 12 weeks. The specific oral dose administered is referenced in the published trial (Neuropsychopharmacology, 2009;34(7):1810–8).
Animal model (dyslipidemia study, ob/ob mice): Cytidine was administered at 0.4 mg/mL in drinking water for five weeks.
Animal model (gerbil plasma study): Gerbils were fed by gavage 250 mg/kg cytidine or uridine. Both dietary cytidine and uridine increased plasma uridine levels by a statistically significant margin relative to control groups, with dietary uridine resulting in plasma uridine levels approximately 3-fold higher than dietary cytidine.
Infant formula: The nucleotides added to infant formulas include cytidine-5′-monophosphate among others. These substances are important metabolic regulators, involved in energy transfer and breaking down large molecules, and are particularly important in tissues with rapid turnover.
Citicoline (as a cytidine-releasing supplement): Citicoline supplementation trials in healthy adults have used doses of 250–500 mg, with this range reported in two clinical trials on healthy adults. As a dietary supplement, citicoline is available over the counter in the United States and as a prescription drug in Europe and Japan.

No established tolerable upper intake level or recommended dietary allowance (RDA) has been set for cytidine by regulatory bodies such as the NIH Office of Dietary Supplements or EFSA at the time of writing.

7. Safety Considerations and Interactions

General Safety Profile

When consumed, much of the cytidine from food is converted to uridine in the intestine and liver before it enters circulation. This rapid first-pass metabolism limits the plasma concentration of unmodified cytidine achievable through oral ingestion of food sources and likely moderates any dose-dependent toxicity.

Long-term human safety data for supplemental cytidine specifically are limited. Studies on citicoline (which liberates cytidine in the gut) represent the closest available safety evidence for cytidine exposure in humans. Citicoline is generally well tolerated with a favorable safety profile; however, some users may experience gastrointestinal disturbances, such as diarrhea, nausea, and abdominal discomfort.

Blood–Brain Barrier Considerations

The blood–brain barrier high-affinity transporter for pyrimidines (CNT2) has a very low affinity for cytidine. This pharmacokinetic characteristic means that, compared with uridine, cytidine has limited direct access to the central nervous system, and its neurobiological effects are likely mediated predominantly through its peripheral conversion to uridine.

Species Differences Relevant to Safety Interpretation

Exogenously administered CDP-choline is metabolized to cytidine and choline in rats, while it is metabolized to uridine and choline in humans. This fundamental species difference means that animal safety studies using exogenous cytidine may not translate directly to human outcomes, and results from rat or mouse models should be interpreted with caution.

Interaction with Pyrimidine Metabolism and Drug Interactions

Cytidine deaminase (CDD) exerts its enzymatic activity not only on its physiologic substrates cytidine and deoxycytidine but also on a number of cytidine analog-type drugs, such as ara-C (cytarabine), gemcitabine, and 5-azacytidine, which may be inactivated by the enzyme. This means that elevated cytidine levels — whether from supplementation or dietary intake — could theoretically compete with certain nucleoside analog chemotherapy drugs that rely on CDD-mediated activation or that are themselves substrates of CDD. This represents a theoretical, not yet clinically confirmed, pharmacokinetic interaction. Individuals undergoing treatment with nucleoside analog chemotherapy agents should be considered at potential risk for such interactions.

Immune Context

As previously known for extracellular uridine, increasing extracellular cytidine protects activated T cells. This immune-protective property suggests that supplemental cytidine, by supporting pyrimidine pools in rapidly dividing lymphocytes, may be relevant in settings of immune stress. However, this finding is based on in vitro and mechanistic research, not human trials.

Nucleotide Supplementation in Infants

Nucleotides have been identified as conditionally essential nutrients, since their de novo presence in rapidly growing tissues is both a functional and structural requirement for proper cell function. The use of CMP and other nucleotides in infant formulas is regulated and subject to defined composition limits by the European Union Infant Formula Directive and similar frameworks.

8. Evidence Summary and Limitations

Cytidine's biochemistry is well characterized in the scientific literature: it is an endogenous pyrimidine nucleoside with indispensable roles in RNA structure, phospholipid membrane synthesis, and cellular metabolism. Its conversion to uridine, and subsequently to CTP via the salvage pathway, underpins its most significant biological actions — particularly in the brain, where CTP availability limits the rate of phosphatidylcholine synthesis.

As a standalone supplement, cytidine has a narrow human clinical evidence base. The only identifiable placebo-controlled RCT testing oral cytidine in humans (n=35, bipolar depression) produced encouraging but preliminary results. No large, replicated, well-powered human clinical trials for cytidine supplementation have been published. Most mechanistic knowledge derives from animal studies, in vitro research, or from citicoline trials in which cytidine is one of two metabolites released after ingestion. Preclinical data on lipid metabolism are intriguing but require human validation.

Researchers and clinicians seeking to understand cytidine's effects in humans must rely primarily on citicoline literature, interpret species differences carefully, and recognize that a robust clinical evidence base for cytidine as a discrete oral supplement has yet to be established.

References

Health Conditions

Health conditions that Cytidine may help support.

No conditions available.

Body Systems

Body systems that Cytidine may help support.

No body systems available.